2013 News Releases

Webcast ImageWebcast
Q3 2017 Clovis Oncology, Inc. Earnings Conference Call (Replay)
11/01/17 at 4:30 p.m. ET
Q3 2017 Clovis Oncology, Inc. Earnings Conference Call
Wednesday, November 1, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Clovis Oncology, Inc. at the Stifel 2017 Healthcare Conference (Replay)
11/15/17 at 9:30 a.m. ET
Clovis Oncology, Inc. at the Stifel 2017 Healthcare Conference
Wednesday, November 15, 2017 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/23/13Clovis Oncology Announces CO-1686 Clinical Data Accepted as Oral Presentation at 2014 European Lung Cancer Conference
BOULDER, Colo.--(BUSINESS WIRE)--Dec. 23, 2013-- Clovis Oncology (NASDAQ:CLVS) announced today that an abstract discussing the findings of the ongoing Phase I portion of the Phase I/II clinical study of CO-1686 has been accepted for Proffered Paper (Oral) presentation during the 4th European Lung Cancer Conference (ELCC). CO-1686 is the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor ... 
Printer Friendly VersionDownload PDF
12/03/13Clovis Oncology Announces Sale of Shares of Common Stock by Selling Stockholders
BOULDER, Colo.--(BUSINESS WIRE)--Dec. 3, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $57.50 per share. All of the shares are being sold by certain existing stockholders who acquired the shares of the Company’s common stock as consideration in connection with the Company’s acquisition of EOS (Ethical Oncology Science) S.p.A. ... 
Printer Friendly VersionDownload PDF
12/02/13Clovis Oncology Announces Proposed Secondary Offering of Shares of Common Stock by Selling Stockholders
No new shares of common stock being sold by the Company BOULDER, Colo.--(BUSINESS WIRE)--Dec. 2, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that certain selling stockholders have commenced an underwritten public offering of 2,000,000 shares of the Company’s common stock which they recently acquired as consideration in connection with the Company’s acquisition of EOS (Ethical Oncology Science) S.p.A. All net pro... 
Printer Friendly VersionDownload PDF
11/19/13Clovis Oncology Acquires EOS (Ethical Oncology Science) S.p.A. to Gain Rights to Lucitanib, a Unique Dual-Selective Phase II FGFR/VEGFR Inhibitor
50 percent response rate seen in heavily-pretreated FGF-aberrant breast cancer patients Activity observed in other solid tumors with FGFR/VEGFR pathway activation Servier partnership to fund majority of lucitanib R&D expenditures over the next 2-3 years Adds third compound to portfolio with focus on patient selection and companion diagnostics BOULDER, Colo.--(BUSINESS... 
Printer Friendly VersionDownload PDF
11/05/13Clovis Oncology to Present at the Credit Suisse Annual Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Nov. 5, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast, the Company’s executive vice president and CFO, will present at the Credit Suisse Annual Healthcare Conference on Tuesday, November 12, at 4:00pm MST. The conference is being held at The Phoenician in Scottsdale, Arizona. A live webcast of the corporate presentation at the conference will be accessible through the investo... 
Printer Friendly VersionDownload PDF
10/31/13Clovis Oncology Announces Third Quarter 2013 Operating Results
CO-1686 and rucaparib demonstrated meaningful clinical activity in data presented at recent medical meetings 67 percent objective response rate demonstrated in heavily pretreated T790M+ NSCLC patients dosed at 900mg BID free base form of CO-1686 Dose escalation continues with improved hydrobromide (HBr) formulation First patient enrolled in ARIEL2 Phase II study of rucaparib in ... 
Printer Friendly VersionDownload PDF
10/30/13Clovis Oncology Announces First Patient Enrolled in ARIEL2 Study of Rucaparib in Ovarian Cancer
Study to utilize DNA sequencing to determine the ovarian cancer patients most likely to benefit from rucaparib BOULDER, Colo.--(BUSINESS WIRE)--Oct. 30, 2013-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the global ARIEL2 (Assessment of Rucaparib in Ovarian Cancer Phase 2 Trial) study of rucaparib has commenced with the dosing of the first patient at a U.S. study site. Rucaparib is the Company’s oral, potent, small molecule poly ... 
Printer Friendly VersionDownload PDF
10/27/13Clovis Oncology’s CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study Results
67 percent objective response rate in heavily pretreated T790M+ patients dosed at 900mg BID of free base formulation New hydrobromide (HBr) formulation shows significantly improved exposures and reduced variability compared with free base in first cohort treated No rash or diarrhea of any grade, or dose-limiting toxicities seen at 500mg BID dose of HBr formulation, despite substantial exposures ... 
Printer Friendly VersionDownload PDF
10/23/13Clovis Oncology to Announce Third Quarter 2013 Financial Results and Host Webcast Conference Call on October 31
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 23, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its third quarter 2013 financial results on Thursday, October 31, 2013, after the market close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on Thursday, October 31, at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be access... 
Printer Friendly VersionDownload PDF
10/21/13Clovis Oncology Announces Lung Cancer Diagnostic Collaboration with QIAGEN
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 21, 2013-- Clovis Oncology (NASDAQ: CLVS) announced today that the Company signed an agreement with QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) to develop a companion diagnostic test to identify the T790M resistance mutation in patients with epidermal growth factor receptor (EGFR) driven non-small cell lung cancer (NSCLC) for CO-1686. The diagnostic will build on QIAGEN’s therascreen® EGFR RGQ... 
Printer Friendly VersionDownload PDF
09/29/13Ongoing Phase I Monotherapy Study of Rucaparib in Patients with Solid Tumors Demonstrates Clinical Activity, Establishes Dose and Schedule
Objective responses seen in BRCA-mutant ovarian, breast and pancreatic cancer patients Disease control rate in BRCA-mutant ovarian cancer patients across all doses of 100% and 63% at 12 weeks and 24 weeks, respectively Rucaparib well-tolerated at recommended Phase II dose of 600 mg BID Consistent therapeutic drug exposures observed with BID dosing BOULDER, Colo.--(BUSINESS WIRE)--Sep. ... 
Printer Friendly VersionDownload PDF
09/04/13Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Sep. 4, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company’s President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013, at 10:00 AM ET. The conference will be held at the Grand Hyatt New York. A live webcast of the presentation can be accessed through the investor relations section of ... 
Printer Friendly VersionDownload PDF
08/28/13Clovis Oncology Announces First Patient Treated with Hydrobromide Salt Tablet Formulation of CO-1686 in its Ongoing Phase I/II Clinical Study
BOULDER, Colo.--(BUSINESS WIRE)--Aug. 28, 2013-- Clovis Oncology (NASDAQ:CLVS) announced today that it has dosed the first patient with its new hydrobromide salt tablet formulation of CO-1686 in its ongoing Phase I dose-finding portion of its Phase I/II clinical study. CO-1686 is the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung can... 
Printer Friendly VersionDownload PDF
08/01/13Clovis Oncology Announces Second Quarter 2013 Operating Results
● Encouraging initial data for both CO-1686 and rucaparib presented at ASCO ● Dose established for rucaparib pivotal program ● Clinical transition to CO-1686 tablet formulation on track for August ● Additional Phase I data updates for CO-1686 and rucaparib expected at medical conferences later this year BOULDER, Colo.--(BUSINESS WIRE)--Aug. 1, 2013-- Clovis Oncology, Inc. (NASDAQ:CLVS) today report... 
Printer Friendly VersionDownload PDF
07/24/13Clovis Oncology to Announce Second Quarter 2013 Financial Results and Host Webcast Conference Call on August 1
BOULDER, Colo.--(BUSINESS WIRE)--Jul. 24, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its second quarter 2013 financial results on Thursday, August 1, 2013, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on Thursday, August 1, at 8:30 a.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from th... 
Printer Friendly VersionDownload PDF
06/13/13Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 13, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 486,110 shares. The offering, including the sale of the additional shares, is expected to close on June 17, 2013, subject to customary closing conditions. Clovis Oncology intends to use t... 
Printer Friendly VersionDownload PDF
06/13/13Clovis Oncology Welcomes Two New Directors to its Board
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 13, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS), announced today the addition of two new members to its Board of Directors, Ginger Graham and Keith Flaherty, M.D. “We are delighted to add these two gifted individuals to our Board of Directors as the Company matures into a later-stage developer of oncology products and ultimately a commercial organization,” said Patrick J. Mahaffy, president and CEO of ... 
Printer Friendly VersionDownload PDF
06/11/13Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 11, 2013-- Clovis Oncology (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,333,334 shares of its common stock at $72.00 per share, before underwriting discounts and commissions. The size of the offering was upsized from $170 million to $240 million. In addition, the underwriters have a 30-day option to purchase up to an additional 486,110 shares of common stock from Clovis Oncology t... 
Printer Friendly VersionDownload PDF
06/10/13Clovis Oncology Announces Proposed Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 10, 2013-- Clovis Oncology (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $170 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology. Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including funding of its development... 
Printer Friendly VersionDownload PDF
06/03/13Clovis Oncology’s CO-1686 Demonstrates Encouraging Results from Ongoing Phase I/II Study in EGFR-mutant Non-Small Cell Lung Cancer
Four RECIST partial responses observed in heavily pretreated T790M+ patients Three of four evaluable T790M+ patients treated at 900 mg BID achieved partial responses CO-1686 appears well-tolerated; no evidence of wild-type EGFR inhibition Activity correlates with higher drug exposure Phase II dose not yet defined; MTD not yet reached BOULDER, Colo.--(B... 
Printer Friendly VersionDownload PDF
06/03/13Clovis Oncology’s Rucaparib Demonstrates Encouraging Results from Ongoing Phase I/II Monotherapy Study in Patients with Solid Tumors
Objective responses seen in BRCA-mutant ovarian, breast and pancreatic cancer patients 89% clinical benefit rate in ovarian cancer patients across all doses Rucaparib well-tolerated at doses studied Consistent therapeutic drug exposures observed with BID dosing Phase II dose not yet defined; MTD not yet reached BOULDER, Colo.--(BUSINESS WIRE)--Jun. 3, 2013-- ... 
Printer Friendly VersionDownload PDF
05/16/13Clovis Oncology Announces Clinical Data to be Presented at ASCO Annual Meeting 2013
BOULDER, Colo.--(BUSINESS WIRE)--May. 16, 2013-- Clovis Oncology (NASDAQ:CLVS) announced that three abstracts (ASCO Abstracts #2524, #2585, #2586) highlighting results from three Phase I studies of the company’s two lead compounds will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 in Chicago. Data contained in the published abstracts was current as of the submission deadline of February 5th, 2013. Dat... 
Printer Friendly VersionDownload PDF
05/08/13Clovis Oncology to Present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas
BOULDER, Colo.--(BUSINESS WIRE)--May. 8, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast, the Company’s Chief Financial Officer and Executive Vice President, will present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 10:40 AM PDT. The conference will be held at the Encore at the Wynn in Las Vegas. A live webcast of the presentation can be accessed through the investor... 
Printer Friendly VersionDownload PDF
05/07/13Clovis Oncology Announces First Quarter 2013 Operating Results
BOULDER, Colo.--(BUSINESS WIRE)--May. 7, 2013-- Clovis Oncology, Inc. (NASDAQ:CLVS) today reported financial results for its first quarter ended March 31, 2013, and provided an update for its clinical development programs. This update describes, for the first time, the Company’s progress in developing a new formulation for CO-1686, including results from a recently initiated pharmacokinetic (PK) study in healthy human volunteers. “D... 
Printer Friendly VersionDownload PDF
04/23/13Clovis Oncology to Announce First Quarter 2013 Financial Results and Host Webcast Conference Call on May 7
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 23, 2013-- Clovis Oncology, Inc. (Nasdaq:CLVS) will announce its first quarter 2013 financial results on Tuesday, May 7, 2013, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on Tuesday, May 7, at 8:30 a.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis ... 
Printer Friendly VersionDownload PDF
02/28/13Clovis Oncology Announces 2012 Operating Results and 2013 Objectives
BOULDER, Colo.--(BUSINESS WIRE)--Feb. 28, 2013-- Clovis Oncology, Inc. (NASDAQ:CLVS) today reported financial results for its quarter and year ended December 31, 2012, and provided an update on the expected milestones for its clinical development programs for 2013. “2012 was an important and eventful year for Clovis, despite the disappointing outcome of the LEAP study in pancreatic cancer,” said Patrick J. Mahaffy, President and CEO... 
Printer Friendly VersionDownload PDF
02/25/13Clovis Oncology to Present at the Cowen Health Care Conference in Boston
BOULDER, Colo.--(BUSINESS WIRE)--Feb. 25, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President of Clovis, will present at the Cowen & Company 33rd Annual Health Care Conference on Monday, March 4, 2013, at 2:10 PM Eastern Time. The conference will be held at the Boston Marriott Copley Place. A live webcast of the presentation can be accessed through the investor rela... 
Printer Friendly VersionDownload PDF
02/14/13Clovis Oncology to Announce Fourth Quarter/Year End 2012 Financial Results and Host Webcast Conference Call on February 28
BOULDER, Colo.--(BUSINESS WIRE)--Feb. 14, 2013-- Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its fourth quarter/year end 2012 financial results on Thursday, February 28, 2013, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on Thursday, February 28, at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can b... 
Printer Friendly VersionDownload PDF
01/07/13Clovis Oncology Announces 2013 Objectives and Financial Guidance
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 7, 2013-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced anticipated development milestones and financial guidance for 2013. Clovis currently has two clinical development programs and one drug discovery program underway. CO-1686 A novel, oral, mutant-selective covalent inhibitor of EGFR mutations in non-small cell lung cancer (NSCLC), CO-1686 is currently the subject of an acce... 
Printer Friendly VersionDownload PDF
01/02/13Clovis Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 2, 2013-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President of Clovis will present at the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2012 at 9:00 AM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation can be accessed through the investor... 
Printer Friendly VersionDownload PDF
Investor Relations and Corporate Communications Contacts
Breanna Burkart
Phone: 303.625.5023
E-mail: bburkart@clovisoncology.com
Anna Sussman
Phone: 303.625.5022
E-mail: asussman@clovisoncology.com